Introduction {#Sec1}
============

Neuronal signal propagation in vertebrates is sped up by the electrical insulation of axons with an ensheathing, specialized glial plasma membrane: myelin. Myelination of axons reduces their transverse capacitance and increases their transverse resistance \[[@CR1]\]. Insulation is achieved by the multilayered arrangement of the myelin membrane (Fig. [1](#Fig1){ref-type="fig"}) and its special molecular composition, mainly its very high lipid content. In myelinated axons, action potentials are restricted to periodically spaced small segments spared from coverage with myelin, termed the nodes of Ranvier \[[@CR2]\]. In the central nervous system (CNS), any individual oligodendrocyte myelinates up to 50 axon segments, termed internodes \[[@CR3]\]. Oligodendrocyte precursor cell division, migration, and regular alignment along the axons have been recently visualized *in vivo* in zebrafish \[[@CR4]\], which today complement rodents as an important model organism for myelin research \[[@CR5]--[@CR8]\]. Myelin formation proceeds with outgrowth and retraction of glial cell processes, target axon recognition, stabilization of cellular contacts, rapid biosynthesis and trafficking of lipid and protein constituents of the myelin membrane, and its organization as a multilayered structure around the axon \[[@CR9], [@CR10]\]. Once myelinated, axons become dependent on glial support \[[@CR11]\]. Some of the molecules involved in myelin development and function are known but a detailed molecular picture has not been gained yet. Fig. 1CNS myelin. **a** Purified mouse brain myelin was one-dimensionally separated in a 4--12% Bis--Tris gradient gel using a morpholineethanesulfonic acid buffer system. Proteins were visualized by colloidal Coomassie staining. Bands constituted by abundant myelin proteins are annotated. **b** Schematic depiction of an oligodendrocyte myelinating an axon, cross-sections in the internodal and paranodal segments, and subcellular localization of myelin proteins. Structural proteins of compact myelin (*middle*), cytoskeletal and vesicular proteins located in uncompacted regions (*right*), and adhesion proteins mediating association with the axon (*bottom*) are shown. *CNP* 2′,3′-cyclic nucleotide phosphodiesterase, *Cntn* contactin, *Caspr* contactin-associated protein, *Cx29* connexin 29 kDa, *DM20* small splice isoform of PLP, *ERM* ezrin, radixin, moesin, *IPL* intraperiod line, *JAM3* junctional adhesion molecule 3, *MAG* myelin-associated glycoprotein, *MBP* myelin basic protein, *MDL* major dense line, *Necl* nectin-like protein, *NF155* neurofascin 155 kDa, *OSP* oligodendrocyte-specific protein/claudin-11, *PLP* proteolipid protein, *Rab3* Ras-related protein Rab3, *SIRT2* sirtuin 2

That CNS myelin is important for normal sensation, cognition, and motor function is obvious considering that myelin-related disorders often affect humans lethally. Besides the inflammatory demyelinating disease multiple sclerosis \[[@CR12]\], there are genetically inherited disorders that affect CNS myelin, collectively termed leukodystrophies \[[@CR13]\]. This heterogeneous group of diseases is characterized by the loss of motoric, sensory, and mental capabilities and the susceptibility to seizures. A detailed knowledge of the molecular expression profiles of oligodendrocytes and myelin will be crucial to understand the pathomechanisms of white matter diseases. For example, the mRNAs \[[@CR14]--[@CR16]\] and proteins expressed in cultivated oligodendrocytes \[[@CR17]\] and oligodendroglial exosomes \[[@CR18]\] have been recently examined. This review focuses on systematic analyses of the molecular composition of mammalian CNS myelin, while no such compendium of peripheral nervous system (PNS) myelin proteins has been published yet. Proteomics approaches to myelin provide a valuable resource to understand its biogenesis, function, and pathology. Although only a few comparative studies have been reported to date, novel insights into the molecular basis of myelin-related diseases are beginning to emerge.

A Myelin-Enriched Fraction from the Central Nervous System {#Sec2}
==========================================================

A comparatively simple method is available for the isolation of a myelin-enriched fraction from the CNS. Biochemically, myelin is defined as the lightweight membranous material accumulating at the interface between 0.32 and 0.85 M sucrose after sequential ultracentrifugation combined with osmotic shocks \[[@CR19], [@CR20]\]. The most commonly used protocol starts from brain homogenate contained in 0.32 M sucrose as the top layer, "spinning-down" myelin to accumulate at the interface with the bottom 0.85 M sucrose layer. One valuable modification is "floating-up" of myelin starting from brain homogenate contained in a more concentrated sucrose solution as the bottom layer (0.85, 1.2, 1.44, or 2 M). During ultracentrifugation, myelin also accumulates at the interface between the upper 0.85 and 0.32 M sucrose layers, while other fractions of interest assemble at higher sucrose concentrations. This method allows the simultaneous isolation of other brain fractions such as rough microsomes \[[@CR21]\] or axogliosomes \[[@CR22], [@CR23]\]. The lightweight fraction from the interphase between 0.32 and 0.85 M sucrose is the most frequently used one for biochemical and proteomic experiments. This fraction is enriched in the most abundant proteins of compact myelin, proteolipid protein (PLP), and myelin basic protein (MBP), and as revealed by electron microscopy, mainly contains multilamellar membranes with a periodicity comparable to that of myelin in native or perfused brains \[[@CR24], [@CR25]\]. However, we suggest to term this fraction "myelin-enriched" rather than "compact myelin", as it also contains proteins from the noncompacted cytosolic channels in myelin (i.e., adaxonal and paranodal myelin) and proteins associated with the axonal membrane. Myelin purification is very reproducible across different laboratories, even when applied to different species (e.g., mouse--rat) or to mutant mice with altered myelin protein or lipid composition, such as Cnp^*Cre/+*^\*Fdft^*flox/flox*^ \[[@CR26]\], Ugt3a1^*null*^ \[[@CR27]\], Arsa^*null*^ \[[@CR28]\], and Plp^*null*^ \[[@CR29]\] (see below). Thus, the method has proven to be very robust, explaining why the original protocol from the early 1970s is still in common use. It is generally assumed that myelin purification relies on its special lipid content and composition.

Myelin Lipids {#Sec3}
=============

The molecular composition of myelin differs from other plasma membranes in that it contains 70--75% of its dry weight as lipid, unusually high compared to other eukaryotic plasma membranes. Also, its molar ratio of lipids with approximately 2:2:1:1 for cholesterol/phospholipid/galactolipid/plasmalogen \[[@CR30], [@CR31]\] distinguishes myelin from other cellular membranes. The abundance of cholesterol within a membrane affects its biophysical properties, including fluidity and curving \[[@CR32]\]. Cholesterol has earlier been identified as unusually enriched in myelin and constitutes 24--28% of the total myelin lipids \[[@CR19]\]. That the cellular cholesterol supply is rate-limiting for myelin membrane biogenesis has been shown in mice lacking squalene synthase (also termed farnesyl diphosphate farnesyl transferase \[FDFT\]) exclusively in myelinating glia \[[@CR26]\]. FDFT mediates a crucial step of cholesterol biosynthesis. CNS myelination is severely delayed in Cnp^*Cre/+*^\*Fdft1^*flox/flox*^ mice, and that any myelin made in these mice is likely due to compensatory cholesterol uptake from other cells \[[@CR26]\].

The biophysical properties of myelin are also influenced by its unusually high concentration of the galactolipids galactosylceramide (GalC), its sulfated form 3-O-sulfogalactosylceramide (SGalC), and their hydroxylated forms GalC-OH and SGalC-OH. Together, they add up to 20--26% of total myelin lipids. Myelination is moderately delayed in mice lacking UDP-galactose:ceramide galactosyltransferase (Ugt3a1), an enzyme required for galactolipid synthesis. Additionally, impaired glia--axonal interactions at the paranodes were observed \[[@CR27], [@CR33], [@CR34]\]. Paranodal disruption was at least partly due to the lack of SGalC and hydroxylated galactolipids, since the long-term integrity of the sodium channel domain of the nodes of Ranvier was also impaired in mice lacking galactosylceramide-3-O-sulfotransferase (Gal3st1), the enzyme converting GalC into SGalC \[[@CR35]--[@CR37]\], and late onset myelin degeneration was also reported for mice lacking fatty acid 2-hydroxylase (Fa2h), the enzyme hydroxylating GalC and SGalC \[[@CR38]\]. Absence of functional arylsulfatase A (ARSA), the enzyme degrading SGalC, causes metachromatic leukodystrophy (MLD), illustrating that a regulated galactolipid metabolism is required for long-term integrity of the white matter. SGalC accumulation and many pathological features of MLD are modeled in Arsa^*null*^ mice and in transgenic mice overexpressing Ugt3a1 or Gal3st1 in neurons or oligodendrocytes \[[@CR28], [@CR39], [@CR40]\]. Sulfatide metabolism with respect to myelin and MLD pathology was recently reviewed \[[@CR41]\].

Also, the plasmalogen class of phospholipids is associated with white matter disease. Plasmalogens are ether-linked (as opposed to ester-linked) phospholipids, the main species being ethanolamine--plasmalogen. They are ubiquitous structural components of mammalian cell membranes and amount to 12--15% of total myelin lipid \[[@CR19]\] and, when processed by plasmalogen-selective phospholipase A2, give rise to the second messengers arachidonic acid and eicosanoids \[[@CR42]\]. At low concentrations, these metabolites have trophic effects, but at high levels, they are cytotoxic and may induce inflammation \[[@CR43]\]. The reactivity of the alkenyl ether bond makes plasmalogens more susceptible to oxidative reactions than their fatty acid ester analogs. Thus, myelin plasmalogens may act as endogenous antioxidants protecting cells from oxidative stress \[[@CR44]\]. Disrupted activity of peroxisomal plasmalogen synthesizing enzymes results in peroxisomal biogenesis disorders such as rhizomelic chondrodysplasia punctata (RCDP) in which hypomyelination of the optic nerve has been observed. Decreased plasmalogen levels \[[@CR45], [@CR46]\] and increased levels of reactive oxygen species \[[@CR47], [@CR48]\] may also contribute to the demyelination in X-linked adrenoleukodystrophy caused by the mutated peroxisomal transporter ABCD1, suggesting that a normal plasmalogen metabolism may prevent peroxisomal- and myelin-related disease. Mice lacking dihydroxyacetonephosphate acyltransferase (DAPAT) model several aspects of the RCDP pathology, including optic nerve hypoplasia \[[@CR49]\]. Interestingly, the association of flotillin-1 and contactin with plasmalogen-deficient brain membrane microdomains was diminished in DAPAT^*null*^ mice \[[@CR49]\], suggesting that the local concentration of membrane lipids dictates the association of particular proteins.

Association of Myelin Lipids and Proteins {#Sec4}
=========================================

Cholesterol assembles with galactolipids and plasmalogens within the plane of the membrane, but how they are enriched to the levels found in myelin is unknown. It has been suggested that lipids are targeted to future myelin membrane by their association with myelin-bound proteins \[[@CR9]\]. SGalC appears to be an example to the contrary. SGalC is associated with myelin and lymphocyte protein (MAL) \[[@CR50]\]. Lack of SGalC and lack of MAL lead to similar paranodal malformation \[[@CR35], [@CR51]\]. The subcellular trafficking of MAL, as well as its abundance in myelin, is determined by SgalC \[[@CR28]\], whereas SGalC abundance is not altered in Mal^*null*^ myelin \[[@CR51]\]. It is likely that other myelin proteins are also incorporated into the sheath by attachment with future myelin membrane because of its special lipid composition. Thus, whether myelin proteins dictate the fate of lipids or vice versa may not be generalized. It appears likely that the association of both molecule classes results in each other's control of abundance and trafficking.

That myelin lipids and proteins are closely associated was suggested earlier after the characterization of two types of protein fractions isolated from the white matter based on their resistance to aqueous or organic solvents or to enzymatic proteolysis. One fraction behaved as a lipid with regard to its solubility and was termed PLP \[[@CR52], [@CR53]\]. PLP was later identified to be the most abundant protein of mammalian CNS myelin. It has a high affinity to phospholipids and cholesterol \[[@CR54]--[@CR56]\], and impaired interactions of mutant PLP with membrane lipids are a likely key step in the molecular pathogenesis of the leukodystrophy Pelizaeus--Merzbacher disease \[[@CR57]\]. The other fraction, termed trypsin-resistant protein residue, was insoluble in organic solvent and attached to the membrane lipid phosphatidylinositol phosphate \[[@CR58], [@CR59]\]. The application of extraction methods by Folch became commonly used to categorize myelin proteins according to their biophysical properties.

More recently, the myelin-enriched brain fraction has been chemically subfractionated by differential detergent extraction at low temperatures, resulting in distinct nonidentical but overlapping assemblies of myelin-associated proteins and lipids that were suggested to represent myelin subcompartments \[[@CR60], [@CR61]\]. Cholesterol- and galactolipid-rich membrane microdomains (also referred to as "lipid rafts") have been suggested to deliver myelin proteins to the plasma membrane \[[@CR62]--[@CR64]\]. The relevance of applying the analysis of biochemical characteristics established for membrane microdomains to such a large structure as myelin has remained debated. However, it is widely accepted now that lipid-associated cell signaling molecules, such as the protein tyrosine kinase fyn, have central roles in myelination \[[@CR65], [@CR66]\].

In oligodendroglial processes, fyn is activated by axonal signals via integrin alpha6beta1 \[[@CR67]\]. Among other fyn substrates \[[@CR68], [@CR69]\], the protein translation repressor heterogeneous nuclear ribonucleoprotein (hnRNP) A2 upon phosphorylation is released from its binding site in the 3′UTR of mRNA encoding MBP \[[@CR70]\], the second-most abundant myelin protein. hnRNP A2 binding represses translation during the translocation of MBP mRNA to distal sites of the cell \[[@CR71]\] where newly translated MBP is directly incorporated into the extending oligodendroglial process \[[@CR21], [@CR72]\]. It is generally assumed that MBP mediates the adhesion of the cytoplasmic surfaces between the individual layers of compact myelin \[[@CR73]\] via binding of its many basic residues with the negatively charged headgroups of membrane lipids. Indeed, membrane association of MBP is controlled by the membrane lipid phosphatidylinositol-(4,5)-bisphosphate \[[@CR74]--[@CR76]\]. For over 30 years, it has been known that MBP is highly heterogeneous due to alternative splicing and multiple post-translational modifications (PTMs) \[[@CR77]\]. More recently, modern mass spectrometric techniques have been used to compare the PTMs of MBP from normal and multiple sclerosis brains with respect to methylation, phosphorylation, and arginine deimination \[[@CR78]\]. PTM alterations affect charge, conformation, and hydrogen bonding of MBP, which may modulate its affinity to the myelin membrane and play a role in myelin compaction and in the pathogenesis of demyelinating diseases. MBP is the only myelin protein that has been shown to be essential for myelin formation, as became obvious with the analysis of the natural mouse mutant *shiverer* and the rat mutant *long evans shaker* \[[@CR79], [@CR80]\], which are severely hypomyelinated. Interestingly, mice lacking fyn are also hypomyelinated \[[@CR81], [@CR82]\], likely due to affected translational regulation of MBP expression \[[@CR70], [@CR83]\]. Together, a multitude of factors affects mRNA transcription and transport, translation at axonal contact sites, or membrane binding of MBP, and we speculate that several myelin proteins with yet unidentified roles affect MBP abundance and function.

Systematic Analysis of the CNS Myelin Protein Composition {#Sec5}
=========================================================

The relative abundance of myelin proteins has previously been calculated based on their binding to Buffalo black \[[@CR84]\], Fast green \[[@CR85]\], or Coomassie blue \[[@CR86]\] after separation in one-dimensional (1D) sodium dodecyl sulfate (SDS)--polyacrylamide gel electrophoresis (PAGE). In these measurements, a small number of proteins was determined to be extraordinarily abundant in CNS myelin. PLP and its smaller splice isoform DM20 accounted for 30--45% of total myelin protein, two of the four MBP splice isoforms for 22--35%, 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) for 4--15%, and all remaining proteins for 5--25% \[[@CR19], [@CR85], [@CR87], [@CR88]\]. Similarly, PNS myelin is also dominated by two proteins, myelin protein zero (MPZ, P0) and MBP, which have been estimated to account for 50--70% and 15%, respectively \[[@CR89]\]. In comparison, the most abundant proteins in a brain fraction enriched for synaptic vesicles are synaptobrevin 2 and synaptophysin, which constitute 8% and 10% of the total synaptic vesicle proteins, respectively, as revealed by quantitative immunoblotting \[[@CR90]\]. How and why myelin proteins are enriched to their unusual relative abundance is unclear, considering that PLP and CNP are not essential for the formation of normal amounts of CNS myelin \[[@CR29], [@CR91], [@CR92]\].

Various proteomic techniques have been applied towards the systematic protein composition analysis of the myelin-enriched fraction. Traditionally, first insights into proteomes of subcellular structures often come from two-dimensional (2D) protein maps generated by utilizing isoelectric focusing (IEF) with immobilized pH gradients in the first and SDS-PAGE in the second dimension (2D-IEF/SDS-PAGE) (Fig. [2](#Fig2){ref-type="fig"}a). Proteins of interest are then excised from the gel, proteolytically digested *in situ*, and finally, identified by mass spectrometry (MS) \[[@CR93]\]. Due to its high resolving power, 2D-IEF/SDS-PAGE can be routinely applied for profiling of proteins from complex mixtures and, as protein integrity is retained, also leads to information on protein abundance and processing \[[@CR94]\]. However, major shortcomings of 2D-IEF/SDS-PAGE concern a limited dynamic range, the display of basic and hydrophobic proteins, and---most importantly---the under-representation of membrane proteins. As myelin is dominated by MBP (a highly basic protein) and PLP (a hydrophobic tetraspan protein), incremental improvements in 2D-IEF/SDS-PAGE technology were required before the first 2D mapping of myelin was presented \[[@CR95]\]. By using the zwitterionic detergent amidosulfobetaine-14 (ASB-14) instead of the most commonly used 3-\[(3-cholamidopropyl)-dimethylammonio\]-1-propanesulfonate (CHAPS) \[[@CR96]\], it was possible to solubilize myelin proteins much more effectively and to identify 98 proteins (91 by MS and seven by immunoblotting) in the myelin-enriched fraction from mouse CNS \[[@CR95]\]. This crucial effect of the solubilization conditions is further underscored by two more recent 2D-IEF/SDS-PAGE mapping studies of similar input material. Thirty-eight myelin-associated proteins were identified in one study after CHAPS solubilization \[[@CR97]\], but 131 proteins were identified in another study with ASB-14 \[[@CR25]\]. Thus, at least in the presence of appropriate detergents, myelin can now be considered as well accessible by 2D-IEF/SDS-PAGE, which not only facilitates protein cataloging but also paves the way for differential myelin proteomics on the basis of the 2D differential fluorescence intensity gel electrophoresis technology (2D-DIGE, see below). It is important to note that all conventional 2D mapping approaches mentioned above failed to appropriately display relatively abundant transmembrane myelin marker proteins such as PLP, myelin-associated glycoprotein (MAG) \[[@CR98]\], myelin oligodendrocyte glycoprotein (MOG) \[[@CR99]\], tetraspanin 2 \[[@CR100]\], M6B \[[@CR101]\], or oligodendrocyte-specific protein (OSP/claudin-11) \[[@CR102]--[@CR104]\]. A potential remedy is to perform the first dimension separation as nonequilibrium pH gradient electrophoresis for the 2D mapping of myelin proteins \[[@CR105]\]. However, although this method appeared promising particularly for displaying highly basic proteins, it did not get as popular as 2D-IEF/SDS-PAGE with immobilized pH gradients, mainly due to limitations in reproducibility and resolution. Fig. 2Gel-based myelin proteome maps. Purified mouse brain myelin was two-dimensionally separated in different gel systems. Proteins were visualized by colloidal Coomassie staining, and spots constituted by selected myelin proteins are indicated. **a** 2D-IEF/SDS-PAGE with IEF in a nonlinear pH gradient (pH 3--10) as the first and gradient SDS-PAGE (8--16% acrylamide) as the second dimension. To improve resolution, myelin was delipidated and precipitated by a methanol/chloroform treatment prior to IEF \[[@CR25]\]. **b** 2D-16-BAC/SDS-PAGE with separation in a 16-BAC gel (10% acrylamide) as the first and gradient SDS-PAGE (8--16% acrylamide) as the second dimension. **c** 2D-CTAB/SDS-PAGE with separation in a CTAB gel (10% acrylamide) as the first and gradient SDS-PAGE (8--16% acrylamide) as the second dimension. To deplete soluble and membrane-associated proteins, myelin was subjected to a multistep wash procedure before separation \[[@CR25]\]. 16-BAC and CTAB resulted in similar spot patterns. 2D-IEF/SDS-PAGE provides good resolution but basic, hydrophobic, and transmembrane proteins are under-represented. 2D-16-BAC/SDS-PAGE and 2D-CTAB/SDS-PAGE lead to efficient representation of basic, hydrophobic, and transmembrane proteins but have a lower resolution since separation occurs by protein size in both dimensions

More complete proteome coverage while retaining the benefits of displaying intact proteins can be reached by the additional use of alternative 2D gel systems. Here, the charge-dependent separation in the first dimension (i.e., the IEF) is replaced by a size-dependent separation in the presence of cationic detergents such as 16-benzyldimethyl-*n*-hexadecylammonium chloride (16-BAC; Fig. [2](#Fig2){ref-type="fig"}b) \[[@CR106]\] or cetyltrimethylammonium bromide (CTAB; Fig. [2](#Fig2){ref-type="fig"}c) \[[@CR107]\]. Due to the similar separation principle in both dimensions, proteins are typically dispersed along a diagonal rather than distributed over the entire gel area. Accordingly, these gel systems have a lower resolution compared to 2D-IEF/SDS-PAGE, but can resolve highly basic and even membrane-spanning proteins \[[@CR108]\]. Application of 2D-16-BAC/SDS-PAGE to mouse CNS myelin resulted in the identification of 62 proteins and readily enabled displaying of the transmembrane myelin proteins PLP, MAG, MOG, and OSP/claudin-11 \[[@CR25]\]. Thus, the combination of 2D-IEF/SDS-PAGE and 2D-16-BAC/SDS-PAGE has, so far, yielded the most comprehensive gel-based proteome compendium of mouse CNS myelin, consisting of 162 nonredundant proteins \[[@CR25]\]. Further technical refinements of the method were established in a recent systematic evaluation of five different cationic detergents for the 2D gel electrophoresis of myelin proteins. Here, 16-BAC was the most effective agent for the separation of myelin proteins in the first dimension, while CTAB was most effective for their solubilization \[[@CR109], [@CR110]\]. As resolution improves, 2D gel electrophoresis with cationic detergents may be combined with the DIGE technology as a future tool for monitoring abundance changes of highly basic and membrane-spanning myelin proteins \[[@CR111]\].

To overcome the limitations of gel-based proteomic methods, in particular those of 2D-IEF/SDS-PAGE, gel-free techniques, commonly referred to as shotgun approaches, have emerged in recent years \[[@CR93], [@CR112]\]. Here, separation at the level of intact proteins is omitted and the protein preparation is proteolytically digested at the expense of information related to protein integrity, such as protein size and charge. Separation takes place at the level of proteolytic peptides before interfacing with MS. The tremendous complexity of such peptide mixtures requires a high resolving power and is, therefore, often addressed by the application of 2D liquid chromatography (2D-LC), usually consisting of strong cation exchange in the first and reversed-phase chromatography in the second dimension*.* In the first application of shotgun proteomics to the myelin-enriched fraction from the mouse CNS \[[@CR97]\], 93 proteins were identified resulting---by combination with 2D-IEF/SDS-PAGE (see above)---in a myelin proteome compendium consisting of 103 proteins. The application of a similar shotgun approach to a myelin-enriched fraction from rat CNS led to the identification of 97 myelin proteins \[[@CR23]\]. Both shotgun approaches yielded quite a high overlap of approximately 50% with the so far most comprehensive gel-based library \[[@CR25]\] and contained transmembrane myelin proteins such as PLP, MAG, and MOG.

Relative Abundance of Myelin Proteins {#Sec6}
=====================================

To understand myelin biogenesis and pathology, a comprehensive knowledge of the proteins associated with myelin is a prerequisite. We have confirmed and expanded the previous myelin protein compendia by applying nanoscale 1D ultra performance liquid chromatography (1D-UP-LC) separation coupled to detection with a quadrupole time-of-flight (QTOF) mass spectrometer (Tenzer et al., unpublished). Data were acquired by LC-MS using an alternating low (MS) and elevated (MS^E^) collision energy mode of acquisition (LC-MS^E^), which allows simultaneous identification and label-free relative quantification of the proteins in the sample \[[@CR113]--[@CR115]\]. The identified peptides were annotated to a total of 294 myelin-associated proteins (Table [1](#Tab1){ref-type="table"}) based on a minimum of two peptides per protein with an effective false-positive rate of \<0.2%. They showed a very good overlap of 141 proteins that were also detected in previous myelin proteome analyses and included several established myelin markers (Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). We have calculated the relative abundance of the myelin-associated proteins based on the average intensity of the three most abundant peptides per protein. In the few cases where only two peptides were identified, their average intensity was used. Strikingly, PLP, MBP, and CNP constituted only 17%, 8%, and 4% of the total myelin-associated proteins, respectively (Fig. [4](#Fig4){ref-type="fig"}). All previously known myelin proteins together constituted 35%, while newly identified myelin-associated proteins accounted for 65%. These quantifications take into question previous estimates based on conventional techniques (Fig. [4](#Fig4){ref-type="fig"}b and see above). We suggest that the complexity of myelin protein composition has been overlooked because low abundant proteins did not constitute significant bands on gels when compared to the highly abundant PLP and MBP due to limitations concerning gel separation and/or protein staining. Table 1The CNS myelin proteomeProtein nameIDGeneReferenceA: Known myelin proteinsCD81P35762Cd81ECD9P40240Cd9NDClaudin 11, OSPQ60771Cldn11B,S,T,ECNPP16330CnpW,B,S,R,T,EContactin 1P12960Cntn1B,S,R,T,EErminQ5EBJ4ErmnEEzrinP26040EzrW,T,EGlycoprotein M6BP35803Gpm6bEMyelin and lymphocyte proteinO09198MalND, T (blot)Myelin-associated glycoproteinP20917MagB,S,R,EMyelin basic proteinP04370MbpW,B,S,V,R,EMyelin oligodendrocyte glycoproteinQ61885MogB,S,R,EMyelin protein zero, P0P27573MpzRMyelin proteolipid proteinP60202Plp1B,S,R,T,EMyelin/oligodendrocyte basic proteinQ9D2P8MobpENecl1, Ig superfamily member 4bQ99N28Cadm3SNecl4, Ig superfamily member 4cQ8R464Cadm4S,ENeural cell adhesion molecule 1P13595Ncam1W,S,R,T,ENeurofascinQ810U3NfascB,R,EOligodendrocyte myelin glycoproteinQ63912OmgNDOpalin, TMP10Q7M750OpalinR,EPlasmolipinQ9DCU2PllpERas-related protein Rab 3AP63011Rab3aERas-related protein Rab 3CP62823Rab3cESirtuin 2Q8VDQ8Sirt2W,S,V,R,T,ETetraspanin 2Q922J6Tspan2EB: Newly identified myelin-associated proteins14-3-3 protein betaQ9CQV8YwhabE14-3-3 protein epsilonP62259YwhaeS,R,E14-3-3 protein etaP68510YwhahE14-3-3 protein gammaP61982YwhagW,V,R,T,E14-3-3 protein sigma, stratifinO70456SfnE14-3-3 protein thetaP68254YwhaqE14-3-3 protein zeta deltaP63101YwhazS,R,EActin α cardiac muscle 1P68033Actc1EActin α1P68134Acta1EActin αP62737Acta2R,EActin βP60710ActbW,S,V,R,T,EActin γ1P63260Actg1B,EActin γ2P63268Actg2EAcyl-CoA thioesterase 7Q91V12Acot7R,EADAM 23Q9R1V7Adam23EAdenylate cyclase associated 1P40124Cap1TADP ribosylation factor 1P84078Arf1S,T,EADP ribosylation factor 2Q8BSL7Arf2EADP ribosylation factor 3P61205Arf3EADP ribosylation factor 4P61750Arf4EADP ribosylation factor 5P84084Arf5EADP ribosylation factor 6P62331Arf6W,EAldehyde dehydrogenase 1A1P24549Aldh1a1EAldolase A, fructose-bisphosphateP05064AldoaW,S,V,R,T,EAldolase C, fructose bisphosphateP05063AldocR,T,EAmphiphysin 2, bridging integrator 1O08539Bin1EAnillinQ8K298AnlnR,EAnnexin A2P07356Anxa2EAnnexin A6P14824Anxa6R,TArgininosuccinate synthase 1P16460Ass1B,Eα-SynucleinO55042SncaEBand 4.1 like protein 3Q9WV92Epb4.1l3EBrain acid soluble protein 1, NAP22Q91XV3Basp1S,EBreast carcinoma amplified seq 1Q80YN3Bcas1S,Eβ-SynucleinQ91ZZ3SncbECa^++^ ATPase 1Q3TSK3Atp2b1ECa^++^ ATPase 2Q9R0K7Atp2b2ECa^++^ ATPase 3Q0VF55Atp2b3ECa^++^ ATPase 4Q6Q476Atp2b4ECalmodulin CaMP62204Calm3S,V,ECalnexinP35564CanxB,RCalpain 5O08688Capn5TCaM kinase IIαP11798Camk2aECaM kinase IIβP28652Camk2bECaM kinase IIδQ6PHZ2Camk2dECaM kinase IIγQ923T9Camk2gECannabinoid receptor interacting 1Q5M8N0Cnrip1W,ECarbonic anhydrase 2P00920Car2W,S,T,ECD47, integrin signal transducerQ61735Cd47ECD82P40237Cd82ECDGSH iron sulfur domain 1Q91WS0Cisd1ECell cycle exit and neuronal diff.Q9JKC6Cend1ECell division control protein 42P60766Cdc42W,ECentractin αP61164Actr1aWCholine transporter CD92Q6X893Slc44a1EClathrin heavy chainQ68FD5CltcB,R,ECofilin 1P18760Cfl1S,V,T,ECofilin 2P45591Cfl2EContactin associated protein 1O54991Cntnap1B,ECoronin 1CQ9WUM4Coro1cECreatine kinase brainQ04447CkbW,S,V,R,T,ECrystallin α2P23927CryabW,S,T,ECyclophilin AP17742PpiaW,S,V,ECysteine and glycine rich protein 1P97315Csrp1ECytokeratin 1P04104Krt1ECytokeratin 1BQ6IFZ6Krt77ECytokeratin 5Q922U2Krt5ECytokeratin 6AP50446Krt6aECytokeratin 6GQ9R0H5Krt71ECytokeratin 10P02535Krt10R,ECytokeratin 16Q9Z2K1Krt16EDesminP31001DesEDestrinQ9R0P5DstnEDihydropyrimidinase-like 1,CRMP1P97427Crmp1EDihydropyrimidinase-like 2,CRMP2O08553Dpysl2W,B,S,V,R,T,EDihydropyrimidinase-like 3,CRMP4Q62188Dpysl3EDihydropyrimidinase-like 4,CRMP3O35098Dpysl4EDipeptidylpeptidase 6Q9Z218Dpp6TDown syndrome cell adhesion like 1Q8R4B4Dscaml1EDynactin 2Q99KJ8Dctn2VDynamin 1P39053Dnm1W,B,R,T,EDynamin 2P39054Dnm2EDynamin 3Q8BZ98Dnm3RDynein heavy chainQ9JHU4Dync1h1REctonucleotide pyrophosphatase 6Q8BGN3Enpp6EEH domain containing protein 1Q9WVK4Ehd1B,S,T,EEH domain containing protein 3Q9QXY6Ehd3B,EEH domain containing protein 4Q9EQP2Ehd4EElongation factor 1α1P10126Eef1a1W,B,S,R,EElongation factor 1α2P62631Eef1a2W,B,EElongation factor 1βO70251Eef1b2TElongation factor 2P58252Eef2TEndonuclease domain containing 1Q8C522Endod1EEnolase 1, non-neuronalP17182Eno1W,B,S,V,T,EEnolase 2, neuronalP17183Eno2W,S,V,T,EEnolase 3, muscleP21550Eno3EFascinQ61553Fscn1W,EFatty acid synthaseP19096FasnRFK506 binding protein 1aP26883Fkbp1aS,EFlotillin 1O08917Flot1ND, T (blot)G protein α transducing 1P20612Gnat1EG protein α transducing 2P50149Gnat2EG protein α transducing 3Q3V3I2Gnat3EG protein α11P21278Gna11EG protein α14P30677Gna14EG protein αI1B2RSH2Gnai1EG protein αI2P08752Gnai2EG protein αI3Q9DC51Gnai3EG protein αO1P18872Gnao1S,T,EG protein αO2P18873Gna0B,T,EG protein αqP21279GnaqT,EG protein αSP63094GnasS,EG protein αS olfactoryQ8CGK7GnalEG protein β1P62874Gnb1W,S,V,T,EG protein β2P62880Gnb2W,V,R,EG protein β3Q61011Gnb3EG protein β4P29387Gnb4W,EG protein β5P62881Gnb5WG protein γ12Q9DAS9Gng12EGAPDHP16858GapdhW,S,V,T,EGAPDH spermQ64467GapdhsEGelsolinP13020GsnV,R,TGlial fibrillary acidic proteinP03995GfapW,BGlucose-6-phosphate isomeraseP06745Gpi1B,R,EGlutamate oxaloacetate transaminaseP05201Got1EGlutamate transporter GLASTP56564Slc1a3EGlutamate transporter GLT1P43006Slc1a2R,EGlutamine synthetaseP15105GlulW,S,V,T,EGlutathione S transferase micros. 3Q9CPU4Mgst3EGlutathione S transferase Mu1P10649Gstm1W,EGlutathione S transferase Mu2P15626Gstm2EGlutathione S transferase Mu6O35660Gstm6EGlutathione S transferase P1P19157Gstp1S,V,EGlutathione S transferase P2P46425Gstp2TGrowth associated protein 43P06837Gap43TGTPase RanP62827RanEH^+^/K^+^ ATPase α1Q64436Atp4aEH^+^/K^+^ ATPase α2Q9Z1W8Atp12aEHeat shock 70 kDa protein 1AQ61696Hspa1aEHeat shock 70 kDa protein 1BP17879Hspa1bR,EHeat shock 70 kDa protein 1LP16627Hspa1lEHeat shock 70 kDa protein 2P17156Hspa2W,B,EHeat shock 70 kDa protein 4Q61316Hspa4THeat shock 70 kDa protein 5P20029Hspa5W,T,EHeat shock 70 kDa protein 8P63017Hspa8W,B,S,V,R,T,EHeat shock 70 kDa protein 12AQ8K0U4Hspa12aEHeat shock protein 90 kDa αA1P07901Hsp90aa1B,EHeat shock protein 90 kDa αB1P11499Hsp90ab1T,EHexokinase 1P17710Hk1T,EHexokinase 2O08528Hk2EIg superfamily member 8, EWI-2Q8R366Igsf8B,S,R,EInternexin α, Neurofilament 66 kDaP46660InaW,B,V,R,T,EJunctional adhesion molecule CQ9D8B7Jam3S,EK^+^ channel A1P16388Kcna1EK^+^ channel A2P63141Kcna2EK^+^ channel A3P16390Kcna3EK^+^ channel B2P62482Kcnab2ELactate dehydrogenase AP06151LdhaT,ELactate dehydrogenase BP16125LdhbW,T,ELactate dehydrogenase CP00342LdhcELeucine rich repeat containing 57Q9D1G5Lrrc57ELeucine rich repeat LGI 3Q8K406Lgi3ELimbic system associated membraneQ8BLK3LsampS,ELymphocyte antigen 6HQ9WUC3Ly6hEMacrophage migration inhibitory factorP34884MifW,S,EMalate dehydrogenaseP14152Mdh1W,S,V,T,EMARCKS related proteinP28667Marcksl1SMicrotubule associated protein 1BP14873Mtap1bEMicrotubule associated protein 6Q7TSJ2Mtap6EMicrotubule associated protein tauP10637MaptEMitogen activated protein kinase 1P63085Mapk1EMoesinP26041MsnW,EMunc 18, syntaxin binding protein 1O08599Stxbp1B,R,T,EMyosin IdQ5SYD0Myo1dB,R,ENa^+^/K^+^ ATPase α1Q8VDN2Atp1a1B,S,R,ENa^+^/K^+^ ATPase α2Q6PIE5Atp1a2B,R,ENa^+^/K^+^ ATPase α3Q6PIC6Atp1a3B,R,ENa^+^/K^+^ ATPase α4Q9WV27Atp1a4ENa^+^/K^+^ ATPase β1P14094Atp1b1B,S,R,ENa^+^/K^+^ ATPase β3P97370Atp1b3ENa^+^/K^+^/Cl^−^ cotransporterP55012Slc12a2EN-ethylmaleimide sensitive fusionP46460NsfW,B,R,T,ENeurocalcin δQ91X97NcaldSNeurofilament HP19246NefhW,B,ENeurofilament LP08551NeflW,B,V,R,ENeurofilament MP08553NefmB,R,ENeuroligin 1Q99K10Nlgn1TNeurotriminQ99PJ0HntEN-myc downstream regulatedQ62433Ndrg1W,S,V,T,ENucleoside diphosphate kinase AP15532Nme1W,S,T,ENucleoside diphosphate kinase BQ01768Nme2W,S,T,EParkinson disease protein 7Q99LX0Park7EPeroxiredoxin 1P35700Prdx1W,V,R,T,EPeroxiredoxin 2Q61171Prdx2W,V,EPeroxiredoxin 5P99029Prdx5S,EPhosphatidylethanolamine binding 1P70296Pebp1W,V,EPhosphatidylinositol transfer αP53810PitpnaWPhosphofructokinase 1P47857PfkmEPhosphoglycerate dehydrogenaseQ61753PhgdhWPhosphoglycerate kinase 1P09411Pgk1S,V,T,EPhosphoglycerate kinase 2P09041Pgk2EPhosphoglycerate mutase 1Q9DBJ1Pgam1W,S,T,EPhospholipase Cβ1Q9Z1B3Plcb1W,T,EPhosphoserine aminotransferaseQ99K85Psat1RPrion proteinP04925PrnpEPrion protein dubletQ9QYT9PrndEProgrammed cell death 6 interactingQ9WU78Pdcd6ipWProhibitinP67778PhbW,B,EProhibitin 2O35129Phb2EProtein arginine deiminase 2Q08642Padi2EProtein disulfide isomerase A3P27773Pdia3W,TProtein kinase CγP63318PrkccEPyruvate kinase isozyme M2P52480Pkm2W,S,V,T,EQuinoid dihydropteridine reductaseQ8BVI4QdprERab 1AP62821Rab1ERab 1BQ9D1G1Rab1bERab 2AP53994Rab2aR,ERab 2BP59279Rab2bERab 3BQ9CZT8Rab3bERab 3DP35276Rab3dERab 4AP56371Rab4aERab 4BQ91ZR1Rab4bERab 5CP35278Rab5cERab 7AP51150Rab7RRab 8AP55258Rab8aERab 8BP61028Rab8bERab 10P61027Rab10S,ERab 12P35283Rab12ERab 13Q9DD03Rab13ERab 14Q91V41Rab14ERab 15Q8K386Rab15ERab 18P35293Rab18ERab 26Q504M8Rab26ERab 30Q923S9Rab30ERab 35Q6PHN9Rab35ERab 37Q9JKM7Rab37ERab 39BQ8BHC1Rab39bERab 43Q8CG50Rab43ERab GDP dissociation inhibitor αP50396Gdi1W,S,R,T,ERab GDP dissociation inhibitor βQ61598Gdi2W,T,ERac1P63001Rac1S,R,ERac2Q05144Rac2ERac3P60764Rac3ERadixinP26043RdxW,ERas-related protein Ral AP63321RalaB,ERas-related protein Ral BQ9JIW9RalbERas-related protein Rap 1AP62835Rap1aW,S,R,T,ERas-related protein Rap 1BQ99JI6Rap1bERas-related protein Rap 2aQ80ZJ1Rap2aRReticulon 3Q9ES97Rtn3RRho GDP dissociation inhibitor 1Q99PT1ArhgdiaV,TRhoAQ9QUI0RhoaERhoBP62746RhobT,ERhoCQ62159RhocERhoGP84096RhogES-100βP50114S100bRSeptin 2P42208Sept2W,B,S,T,ESeptin 4P28661Sept4W,ESeptin 7O55131Sept7W,B,S,R,T,ESeptin 8Q8CHH9Sept8W,B,S,V,R,T,ESeptin 11Q8C1B7Sept11ESideroflexin 3Q91V61Sfxn3ESoluble NSF attachment protein αQ9DB05NapaWSoluble NSF attachment protein βP28663NapbW,ESoluble NSF attachment protein γQ9CWZ7NapgWSpectrin α2P16546Spna2B,T,ESpectrin β2Q62261Spnb2R,EStress induced phosphoprotein 1Q60864Stip1W,TSuperoxide dismutaseP08228Sod1W,SSynapsin 1O88935Syn1W,ESynapsin 2Q64332Syn2W,ESynaptic vesicle membrane proteinQ62465Vat1R,TSynaptobrevin 2P63044Vamp2ESynaptobrevin 3P63024Vamp3ESynaptophysinQ62277SypESynaptosomal associated protein 23O09044Snap23ESynaptosomal associated protein 25P60879Snap25W,S,V,R,ESynaptotagmin 1P46096Syt1ESynaptotagmin 5Q9R0N5Syt5ESyndapin 1Q61644Pacsin1W,ESyntaxin 1AO35526Stx1aESyntaxin 1BP61264Stx1bS,R,ET-complex 1αP11983Tcp1WT-complex 1βP80314Cct2WT-complex 1δP80315Cct4RT-complex 1εP80316Cct5WT-complex 1γP80318Cct3WThy 1 membrane glycoproteinP01831Thy1W,S,R,ETransgelin 3Q9R1Q8Tagln3W,ETransitional ER ATPaseQ01853VcpW,T,ETransketolaseP40142TktW,B,S,T,ETriosephosphate isomeraseP17751Tpi1S,ETubulin α1AP68369Tuba1aW,B,R,ETubulin α1BP05213Tuba1bW,S,V,T,ETubulin α1CP68373Tuba1cETubulin α3AP05214Tuba3aETubulin α4AP68368Tuba4aETubulin α8Q9JJZ2Tuba8ETubulin β2AQ7TMM9Tubb2aT,ETubulin β2BQ9CWF2Tubb2bETubulin β2CP68372Tubb2cW,B,S,R,ETubulin β3Q9ERD7Tubb3ETubulin β4Q9D6F9Tubb4W,B,S,V,R,ETubulin β5P99024Tubb5ETubulin β6Q922F4Tubb6R,ETubulin polymerization promotingQ7TQD2TpppW,ETubulin polymerization promoting 3Q9CRB6Tppp3S,EUbiquitinP62991UbW,S,EUbiquitin activating enzyme E1Q02053Uba1TUbiquitin C-terminal hydrolase L1Q9R0P9Uchl1W,T,EVacuolar ATP synthase AP50516Atp6v1aW,EVacuolar ATP synthase B, brainP62814Atp6v1b2W,EVacuolar ATP synthase CQ9Z1G3Atp6v1c1T,EVacuolar ATP synthase E1P50518Atp6v1e1T,EVimentinP20152VimEVisinin like protein 1P62761Vsnl1S,R,EVisinin like protein 3P62748Hpcal1SWD repeat protein 1O88342Wdr1WProteins identified in purified CNS myelin by MS*ID* Swissprot or Trembl accession, *Gene* official NCBI Entrez gene name, *Reference* and method of detection, *T* 2D-IEF/SDS-PAGE or immunoblotting \[[@CR95]\], *V* 2D-IEF/SDS-PAGE \[[@CR97]\], *W* 2D-IEF/SDS-PAGE \[[@CR25]\], *B* 2D-16-BAC/SDS-PAGE \[[@CR25]\], *R* shotgun \[[@CR23]\], *S* shotgun \[[@CR97]\], *E* LC-MS^E^ (Tenzer et al., unpublished), *ND* not detected by MSFig. 3Assembling a compendium of myelin proteins. **a** The number of proteins identified by MS in different approaches to the CNS myelin proteome is plotted. The total number of myelin-associated proteins is unknown. Transmembrane proteins (*black*) have been categorized based on prior experimental studies or have been predicted using TMHMM and Phobius software. Proteins associated with mitochondria, which copurify with myelin, were omitted. *T* 2D-IEF/SDS-PAGE \[[@CR95]\], *V* 2D-IEF/SDS-PAGE \[[@CR97]\], *W* 2D-IEF/SDS-PAGE \[[@CR25]\], *B* 2D-16-BAC/SDS-PAGE \[[@CR25]\], *R* shotgun \[[@CR23]\], *S* shotgun \[[@CR97]\], *E* LC-MS^E^ (Tenzer et al., unpublished). **b** Venn diagram comparing the number of myelin-associated proteins identified by MS after gel separation \[[@CR25], [@CR95], [@CR97]\], previous gel-free shotgun approaches by LC/LC-MS/MS \[[@CR23], [@CR97]\], with those identified by LC-MS^E^ (Tenzer et al., unpublished). Note the high overlap of proteins identified independent of the technique used. **c** Venn diagram showing our own experience with the identification of myelin-associated proteins by MS after combined 2D-IEF/SDS-PAGE and 2D-16-BAC/SDS-PAGE separation \[[@CR25]\] or by LC-MS^E^ with known myelin proteins according to the literatureFig. 4Relative abundance of myelin proteins. **a** The abundance of known myelin proteins was determined by LC-MS^E^. Note that known myelin proteins constitute less than 50% of the total myelin protein. Mitochondrial proteins were not considered. **b** Comparison of myelin protein abundance as quantified by LC-MS^E^ with previous estimates based on band intensity after 1D-PAGE and various protein staining techniques \[[@CR19], [@CR85], [@CR87], [@CR88]\]. Note that the abundance of PLP and MBP was previously overestimated because low abundant proteins did not constitute significant bands due to limitations in the resolving power of the 1D gels and in the dynamic range of protein staining. **c** Simulated 2D map of myelin-associated proteins identified by LC-MS^E^. Proteins are indicated as *dots* at their molecular weight and isoelectric point as predicted from the amino acid sequence. The size of each dot reflects the relative abundance as determined by LC-MS^E^. Myelin-associated proteins without transmembrane domains are shown in *blue* and transmembrane proteins in *green*, the latter being usually under-represented or absent from conventional 2D gels. Mitochondrial proteins are shown in *gray*. The *red frame* indicates the portion of proteins that can be reproducibly displayed by 2D-IEF/SDS-PAGE (see Fig. [2](#Fig2){ref-type="fig"}a)

We conclude that modern LC-MS-based approaches---though technically more demanding than gel-based studies---appear to be appropriate for tackling the myelin proteome as they cover several orders of magnitude of protein abundance and detect highly basic, hydrophobic, and membrane-spanning proteins. This tackles the bias towards certain protein classes, which is the major shortcoming particularly of 2D-IEF/SDS-PAGE (Fig. [4](#Fig4){ref-type="fig"}c). Moreover, LC-MS-based approaches enable the gel- and label-free quantification of proteins from complex mixtures, which allowed for the systematic reassignment of protein abundance in CNS myelin (see above). Finally, they require only low amounts of sample, which is of special relevance for the proteome analysis of myelin purified from hypomyelinated model animals or human brain autopsy material.

Technical Limitations {#Sec7}
=====================

How pure is the myelin-enriched fraction? Myelin-associated proteins are defined as proteins in the myelin-enriched fraction since all studies have operationally defined the term "myelin protein" without systematic experimental verification. Although the identification of new myelin proteins by more than one study and the detection of established myelin markers increase confidence, some of these proteins may only have copurified with myelin. The high dynamic range of LC-MS^E^ leads to the new identification of proteins as myelin-associated, but also to the false-positive identification of contaminants. These mainly stem from copurifying mitochondria and synaptic vesicles. In reverse, proteomic compendia of mammalian brain mitochondria \[[@CR116]\] or synaptic vesicles \[[@CR90]\] include classical myelin proteins such as PLP, MBP, MOBP, and MAG. Notwithstanding that some of these proteins may have a dual localization, cross-contamination occurs likely due to similar floatation properties in sucrose or Percoll gradients and can only be excluded once improved separation protocols become available. Proteins of the axonal plasma membrane, such as potassium channels or Na^+^/K^+^-ATPases, have also been detected in the myelin fraction, which can be explained by the tight linkage of the membranes via adhesion proteins, sometimes referred to as the myelin--axolemma complex \[[@CR24]\]. Indeed, some adhesion complexes are present in the myelin-enriched fraction, such as the glial neurofascin (NF155) and contactin and their axonal partner contactin associated protein 1 (Caspr) \[[@CR117]--[@CR120]\] and the glial nectin-like protein Necl4 and its axonal counterpart Necl1 \[[@CR121]--[@CR124]\]. Importantly, myelin proteome analysis also revealed novel candidate proteins to mediate intracellular or intercellular adhesion, such as the immunoglobulin domain superfamily protein Igsf8, also termed EWI-2 \[[@CR23]\]. Igsf8 is associated with the myelin tetraspanins CD9 and CD81 and regulates integrin function, at least *in vitro* \[[@CR125], [@CR126]\], but its function *in vivo* remains to be shown. The experimental validation or falsification of newly identified myelin-associated proteins will be a matter of the systematic application of histological techniques, provided that reliable antibodies are available.

How many proteins can be considered true myelin proteins? Though proteomic compendia aim at completeness, the number can only be guessed at this time. As the dynamic range of current MS-based protein identification schemes is in the range of three to five orders of magnitude, detection of infrequent proteins remains a challenge. Additionally, some technical impediments remain. The myelin proteins CD9 \[[@CR127], [@CR128]\], oligodendrocyte myelin glycoprotein \[[@CR22], [@CR129]\], and MAL \[[@CR51]\] have not yet been detected by proteomic approaches, and the appearance of MAL in one catalog \[[@CR95]\] is due to the additional use of immunoblotting. Its nondetectability illustrates the limitations of proteome analysis. MAL is a very hydrophobic protein with four transmembrane domains and very small cytoplasmic and extracellular domains and is, therefore, hardly accessible by MS-based identification. Apart from the membrane-spanning peptides not visible in proteomic approaches, complete tryptic digest of MAL results in only four theoretically detectable peptides: one of 120 amino acids (which is too long for identification by MS), two of two amino acids each (too short to provide useful sequence information), and one of 29 amino acids, which is, in principle, appropriate for identification. However, to obtain a reasonable level of confidence for protein identification, the detection of two peptides per protein is usually set as a prerequisite in the algorithms. This suggests that all proteome approaches requiring protease cleavage have an inherent bias against very small polypeptides or proteins with an unusual cleavage site pattern. In future experiments, the lack of suitable trypsin cleavage sites may be circumvented by the use of endopeptidases with different specificities (e.g., GluC or AspN), although they create proteolytic peptides lacking a basic C-terminal amino acid and are difficult to sequence \[[@CR130]\]. This suggests that the detection of more myelin-associated proteins is not just a matter of higher resolving power but also of other technical refinements.

Newly Identified Myelin-Associated Proteins {#Sec8}
===========================================

The compendium of proteins identified in the myelin-enriched brain fraction represents a valuable reference for myelin research. The proteins are candidates for performing important functions in myelin biogenesis and integrity, molecular interactions between myelinating glia and neighboring cells, and white matter homeostasis. By gene ontology terms (<http://david.abcc.ncifcrf.gov>), many myelin-associated proteins are implicated in catalytic activities (48%), the cytoskeleton (20%), protein transport (21%), vesicular trafficking (6.8%), cell adhesion (6.3%), phospholipid binding (4.2%), or glycolysis/gluconeogenesis (5.1%). Among the recently identified myelin proteins, some were first and others subsequently detected using proteomic approaches. They include proteins of quite various anticipated functions, such as the NAD^+^-dependent deacetylase sirtuin 2 (SIRT2, see below), cytoskeletal proteins of the septin family \[[@CR23], [@CR25], [@CR131]\], and ermin \[[@CR132]\], regulators of intracellular vesicle transport in the secretory pathway, such as cdc42 and Rac1 \[[@CR133]\], Rab3A, and other Rab-GTPases \[[@CR134], [@CR135]\], the paranodal transmembrane glycoprotein Opalin/TMEM10 with a suggested signaling or adhesive function \[[@CR136]--[@CR138]\], the nucleoside diphosphate kinases NM23A and NM23B \[[@CR95]\], and a protein particularly abundant in the CNS myelin of teleost fish, the 36K protein, also termed short-chain dehydrogenase/reductase (SDR family) member 12 (DHRS12) \[[@CR139]\]. Some of these are quite abundant myelin proteins as judged both by the spots constituted on 2D gels and LC-based quantification, and the challenge to establish their functions *in vivo* promises a deepened understanding of myelin. Besides, novel myelin proteins are candidates to cause (when mutated), enhance, or ameliorate white matter disease, such as leukodystrophies.

Differential Myelin Proteome Analysis in Myelin-Related Disease {#Sec9}
===============================================================

The proteomic comparison of myelin from human patients or animal models with that of respective controls is a powerful approach towards the identification of secondary molecular changes that may contribute to the pathogenesis of myelin-related disease. Such a differential approach has first been applied to myelin purified from PLP^*null*^ mice \[[@CR25]\], which provide a genuine model for spastic paraplegia (SPG-2) in humans, a comparatively mild variant of the leukodystrophy Pelizaeus--Merzbacher Disease with progressive axonal degeneration in the presence of normal amounts of CNS myelin \[[@CR29], [@CR140]\]. In that study, 2D-DIGE \[[@CR141]\] was used to screen for candidate proteins that could be involved in the oligodendroglial failure to support the long-term integrity of myelinated axons. Three distinct proteins of the cytoskeletal septin family were found to be reduced, and the deacetylase SIRT2 was virtually absent from PLP^*null*^ myelin. SIRT2 is an abundant myelin protein in the CNS and the PNS \[[@CR23], [@CR25], [@CR142]\] and regulates microtubule dynamics during oligodendrocyte development \[[@CR143]\]. Whether acetylated α-tubulin is a relevant substrate of SIRT2 *in vivo* remains to be shown. Similar to PLP^*null*^ mice, CNP^*null*^ mice are also normally myelinated but develop length-dependent axonal loss \[[@CR92], [@CR144]\]. It is intriguing that CNP also modulates microtubule dynamics \[[@CR145], [@CR146]\]. Taken together, spatiotemporal control of microtubule stability in oligodendrocytes (by SIRT2, CNP, and likely other factors) seems critical for normal axon--glia interaction.

Acetylation is a reversible post-translational modification of numerous mammalian proteins \[[@CR147], [@CR148]\], and all acetylated myelin proteins (α-tubulin, MBP, MOG, and several nonidentified proteins of lower abundance) are candidate substrates for SIRT2 \[[@CR25]\]. In oligodendrocytes and myelin, SIRT2 activation upon increased axonal NAD^+^ levels may remove acetyl residues from myelin-associated proteins with consequences for their net charge and function. Interestingly, SIRT2 has been recently shown to interact with 14-3-3 beta and gamma \[[@CR149]\], which are myelin-associated as revealed by proteome analysis (Table [1](#Tab1){ref-type="table"}). Their interaction is strengthened by the serine/threonine kinase AKT \[[@CR149]\], which is a central signaling molecule for CNS myelination \[[@CR150]\]. 14-3-3 proteins have been implicated in membrane protein transport, exocytosis \[[@CR151]\], and stress response \[[@CR152]\], but their function in myelin has not yet been investigated. 14-3-3 proteins are homologs of the *C. elegans* partitioning-defective polarity protein Par5 and bind to the tight junction-associated Par3 \[[@CR153], [@CR154]\], which is required for establishing polarity prior to myelination, at least by Schwann cells in the PNS \[[@CR155]\]. To determine whether SIRT2, 14-3-3 proteins, Par-proteins, protein kinases, and tight junctions indeed interact in myelinating glia will be an important topic of future investigation. We speculate that the competence of oligodendrocytes to dynamically react to NAD^+^ level changes in white matter tracts is required for their role in maintaining long-term axonal integrity.

With the objective to identify novel therapeutic targets for the treatment of multiple sclerosis, a systematic proteomic profiling of tissue samples from three brain lesions affected to various degrees (acute plaque, chronic active plaque, and chronic plaque) has recently been performed \[[@CR156]\]. Material from the respective lesion type was collected by laser-capture microdissection and extracted proteins were separated by 1D gel electrophoresis followed by mass spectrometric protein identification. Unexpectedly, five coagulation proteins, including tissue factor and protein C inhibitor, were only present in chronic active plaque characterized by concomitant inflammation and degeneration, a finding that provided new insights in the relationship between the coagulation cascade and inflammation. Most importantly, administration of inhibitors to tissue factor (i.e., hirudin) and protein C inhibitor (i.e., activated protein C \[aPC\]) indeed ameliorated the disease phenotype in experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The anti-inflammatory treatment with engineered aPC variants may develop into an alternative route to a therapy of multiple sclerosis. Together, differential proteome analysis has identified secondary molecular changes that contribute to understanding the pathogenesis of myelin-related disease and support the design of rational treatment strategies.
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